Astellas Pharma Inc.
OTC: ALPMF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Naoki Okamura
- Employees
- 14,754
- Headquarters
- Tokyo, Japan
- IPO year
- 2010
- Market cap
- $26.2B
- Website
- https://www.astellas.com
Loading ALPMF…
Loading profile data…Frequently asked questions about ALPMF
What does Astellas Pharma Inc. (ALPMF) do?
Astellas Pharma Inc. operates as a global pharmaceutical enterprise, encompassing the development, manufacturing, distribution, and commercialization of medicinal products across international markets. Its diverse portfolio features prominent therapies such as XTANDI, an androgen receptor signaling inhibitor for prostate cancer, and XOSPATA, an...
Where does ALPMF trade?
Astellas Pharma Inc. (ALPMF) trades on the Other OTC.
What sector is ALPMF in?
Astellas Pharma Inc. (ALPMF) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Astellas Pharma Inc.?
Naoki Okamura is the chief executive officer of Astellas Pharma Inc. (ALPMF).
Where is Astellas Pharma Inc. headquartered?
Astellas Pharma Inc. is headquartered in Japan.
Does ALPMF pay a dividend?
Yes — Astellas Pharma Inc. (ALPMF) paid a trailing twelve-month dividend of USD 0.51 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did ALPMF go public?
Astellas Pharma Inc. (ALPMF) completed its initial public offering in 2010.